Emerging pharmacological targets in migraine therapy: CGRP and beyond.

Migraine is a common and challenging neurological disorder affecting many people. Current treatments often rely on repurposed medications, leading to frequent treatment failures. Research shows that migraine is not just a vascular issue. It involves complex interactions in various brain regions, including the cortex and brainstem. These areas communicate through multiple signaling molecules and hormones. New treatments are being developed that target these specific molecules. One promising target is calcitonin gene-related peptide (CGRP). Therapies that block CGRP, like "gepants" and monoclonal antibodies, have shown effectiveness. They can help manage pain during migraine attacks and reduce headache frequency. This is especially beneficial for people who do not respond well to existing treatments. Overall, understanding these new targets may lead to better migraine management strategies for patients. Clinical relevance: This research highlights new migraine treatments targeting CGRP, potentially improving outcomes for patients with treatment-resistant migraines.